Navigation Links
Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
Date:6/4/2009

BRAINTREE, Mass., June 4 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that the U.S. District Court for the District of Massachusetts has made a ruling in the Company's lawsuit against Fenwal, Inc.

In January 2009, a jury issued a verdict in favor of Haemonetics, finding that Fenwal's ALYX Component Collection System consumable infringes a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 million in damages for past infringement. On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December 1, 2010 and must pay Haemonetics a 10% royalty on ALYX consumable net sales from January 30, 2009 until December 1, 2010 when the injunction takes effect. In addition, the court awarded pre-judgment interest at 5% on the unpaid damages awarded. These rulings may be appealed by Fenwal and/or Baxter.

Brian Concannon, Haemonetics' President and CEO, said, "This lawsuit was necessary to protect our Company's intellectual property. Haemonetics remains dedicated to serving the blood collection industry and working with customers to deliver blood management solutions to improve patient care and reduce healthcare costs. We are prepared to support customers through this transition period."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Haemonetics Announces Launch of Faster Plasma Collection Protocol
2. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
3. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
4. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
5. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
6. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
7. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
8. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
9. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
10. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):